A New Paradigm for Cancer Immunotherapy: Targeting Immunogenic Cell Death-related Noncoding RNA

Overview

Journal Front Immunol

Date 2025 Feb 7

PMID 39916954

Authors

Guojuan Sun

Ling He

Affiliations

Soon will be listed here.

Abstract

Cancer immunotherapy has shown significant potential in treating several malignancies by stimulating the host immune system to recognize and attack cancer cells. Immunogenic cell death (ICD) can amplify the antitumor immune responses and reverse the immunosuppressive tumor microenvironment, thus increasing the sensitivity of cancer immunotherapy. In recent years, noncoding RNAs (ncRNAs) have emerged as key regulatory factors in ICD and oncologic immunity. Accordingly, ICD-related ncRNAs hold promise as novel therapeutic targets for optimizing the efficacy of cancer immunotherapy. However, the immunomodulatory properties of ICD-related ncRNAs have not yet been comprehensively summarized. Hence, we summarize the current knowledge on ncRNAs involved in ICD and their potential roles in cancer immunotherapy in this review. It deepens our understanding of ncRNAs associated with ICD and provides a new strategy to enhance cancer immunotherapy by specifically targeting the ICD-related ncRNAs.

References

Alshaer W, Zureigat H, Al Karaki A, Al-Kadash A, Gharaibeh L, Hatmal M . siRNA: Mechanism of action, challenges, and therapeutic approaches. Eur J Pharmacol. 2021; 905:174178. DOI: 10.1016/j.ejphar.2021.174178. View

Song W, Wang K, Yang X, Dai W, Fan Z . Long non‑coding RNA BANCR mediates esophageal squamous cell carcinoma progression by regulating the IGF1R/Raf/MEK/ERK pathway via miR‑338‑3p. Int J Mol Med. 2020; 46(4):1377-1388. PMC: 7447317. DOI: 10.3892/ijmm.2020.4687. View

Milani V, Noessner E, Ghose S, Kuppner M, Ahrens B, Scharner A . Heat shock protein 70: role in antigen presentation and immune stimulation. Int J Hyperthermia. 2003; 18(6):563-75. DOI: 10.1080/02656730210166140. View

Pawaria S, Binder R . CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun. 2011; 2:521. PMC: 3356570. DOI: 10.1038/ncomms1524. View

He M, Gu W, Gao Y, Liu Y, Liu J, Li Z . Molecular subtypes and a prognostic model for hepatocellular carcinoma based on immune- and immunogenic cell death-related lncRNAs. Front Immunol. 2022; 13:1043827. PMC: 9720162. DOI: 10.3389/fimmu.2022.1043827. View

Folini M, Bandiera R, Millo E, Gandellini P, Sozzi G, Gasparini P . Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. Cell Prolif. 2007; 40(6):905-20. PMC: 6760699. DOI: 10.1111/j.1365-2184.2007.00470.x. View

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

Fang P, Xiang L, Chen W, Li S, Huang S, Li J . LncRNA GAS5 enhanced the killing effect of NK cell on liver cancer through regulating miR-544/RUNX3. Innate Immun. 2019; 25(2):99-109. PMC: 6830859. DOI: 10.1177/1753425919827632. View

Obeid M, Tesniere A, Ghiringhelli F, Fimia G, Apetoh L, Perfettini J . Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med. 2006; 13(1):54-61. DOI: 10.1038/nm1523. View

10.

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

11.

Arimoto K, Miyauchi S, Liu M, Zhang D . Emerging role of immunogenic cell death in cancer immunotherapy. Front Immunol. 2024; 15:1390263. PMC: 11116615. DOI: 10.3389/fimmu.2024.1390263. View

12.

Yin M, Dong J, Sun C, Liu X, Liu Z, Liu L . Raddeanin A Enhances Mitochondrial DNA-cGAS/STING Axis-Mediated Antitumor Immunity by Targeting Transactive Responsive DNA-Binding Protein 43. Adv Sci (Weinh). 2023; 10(13):e2206737. PMC: 10161045. DOI: 10.1002/advs.202206737. View

13.

Li C, Wang X, Chen T, Li W, Zhou X, Wang L . Huaier Induces Immunogenic Cell Death CircCLASP1/PKR/eIF2α Signaling Pathway in Triple Negative Breast Cancer. Front Cell Dev Biol. 2022; 10:913824. PMC: 9243662. DOI: 10.3389/fcell.2022.913824. View

14.

Tenchov R, Sasso J, Wang X, Liaw W, Chen C, Zhou Q . Exosomes─Nature's Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics. ACS Nano. 2022; 16(11):17802-17846. PMC: 9706680. DOI: 10.1021/acsnano.2c08774. View

15.

Wang T, Gan X . Emerging roles of HMGB1-related lncRNA: from molecular biology to clinical application. Am J Physiol Cell Physiol. 2022; 323(4):C1149-C1160. DOI: 10.1152/ajpcell.00296.2022. View

16.

Li G, Kryczek I, Nam J, Li X, Li S, Li J . LIMIT is an immunogenic lncRNA in cancer immunity and immunotherapy. Nat Cell Biol. 2021; 23(5):526-537. PMC: 8122078. DOI: 10.1038/s41556-021-00672-3. View

17.

Xue J, Suarez J, Minaai M, Li S, Gaudino G, Pass H . HMGB1 as a therapeutic target in disease. J Cell Physiol. 2020; 236(5):3406-3419. PMC: 8104204. DOI: 10.1002/jcp.30125. View

18.

Heilig R, Lee J, Tait S . Mitochondrial DNA in cell death and inflammation. Biochem Soc Trans. 2023; 51(1):457-472. PMC: 9988000. DOI: 10.1042/BST20221525. View

19.

Ahn I, Kang C, Han J . Where should siRNAs go: applicable organs for siRNA drugs. Exp Mol Med. 2023; 55(7):1283-1292. PMC: 10393947. DOI: 10.1038/s12276-023-00998-y. View

20.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P . Consensus guidelines for the detection of immunogenic cell death. Oncoimmunology. 2015; 3(9):e955691. PMC: 4292729. DOI: 10.4161/21624011.2014.955691. View